| Ytd | -9.59% | |
| 1y | 24.50% |
| Open | 5.24 | Prev Close | 5.26 | Low | 5.13 | High | 5.25 | Mkt Cap | 142.72M |
| Vol | 390.19K | Avg Vol | 1.51M | EPS | -1.75 | P/E | N/A | Forward P/E | -3.31 |
| Beta | 1.79 | Short Ratio | 0.74 | Inst. Own | 38.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 5.63 | 200-d Avg | 6.42 | 1yr Est | 5.50 |
UNCY News
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative
Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowe
B. Riley Securities analyst Mayank Mamtani reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a
- Company expects to resubmit New Drug Application (NDA) for oxylanthanum carbonate (OLC) assuming c
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.06) per share which beat the a
Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as cri
BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Block and Leviton is investigating Unicycive Therapeutics,
NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its invest
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder righ
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Unicyci
NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of
Boston, Massachusetts--(Newsfile Corp. - July 6, 2026) - Block & Leviton is investigating Unicycive
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered L
Boston, Massachusetts--(Newsfile Corp. - July 2, 2026) - Block & Leviton is investigating Unicycive
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims aga
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative
Block & Leviton is investigating Unicycive Therapeutics, Inc. (Nasdaq: $UNCY) for possible securitie
Noble Capital Markets analyst Robert LeBoyer maintains Unicycive Therapeutics (NASDAQ:UNCY) with
Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-m
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics (NASDAQ:U
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday&#
B. Riley Securities analyst Mayank Mamtani maintains Unicycive Therapeutics (NASDAQ:UNCY) with a
SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Unicycive Therape
US stocks traded higher, Nasdaq up 150 points. Dow up 0.02%, Nasdaq up 0.68%, S&P 500 up 0.28%.
Unicycive Therapeutics ($UNCY) stock crashes over 46% as FDA rejects kidney disease drug NDA again o
US stocks mixed, Dow falls 0.2%. Leading sectors: tech up 1%, real estate down 1.4%. S&P 500 up
Gainers Abivax (NASDAQ:ABVX) shares increased by 36.0% to $130.74 during Tuesday's pre-market s
Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therap
-- Complete Response Letter relates to deficiencies previously identified at third-party manufacturi
https://www.sec.gov/Archives/edgar/data/1766140/000121390026065819/ea0291789-s3_unicycive.htm
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative
Unicycive Therapeutics is valued at $8/share, with $2/share in cash and the pipeline—primarily OLC—v
Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowe
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.54) per share which missed the
MOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY),
Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Tr
NEW YORK, April 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves
Benchmark analyst Bruce D. Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculat
Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowe
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.82) per share which missed the
The NDA is supported by data from three clinical studies (a Phase 1 study in healthy volunteers, a b
The NDA for OLC was resubmitted based on continued progress by the original third-party manufacturin
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics (NASDAQ:U
Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therap
Benchmark analyst Bruce D. Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculat
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.52) per share which beat the a